PinotBio signed a research and license deal with Switzerland's Alentis Therapeutics to develop next-generation ADCs targeting the claudin-1 protein.
At an age when most children are busy with school, homework and playtime, Illumi Maeda from Japan has earned a place in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results